Re: Brian I. Rini, Tanya B. Dorff, Paul Elson, et al. Active Surveillance in Metastatic Renal-cell Carcinoma: A Prospective, Phase 2 Trial. Lancet Oncol Lancet 2016;17:1317-24: Active Surveillance in Metastatic Renal Cell Carcinoma: Option or Exception?

Affiliations

¹ Unit of Urology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy. Electronic address: umbertocapitanio@gmail.com.
² Unit of Urology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy.

Comment

Umberto Capitanio et al. Eur Urol. 2017 May.

. 2017 May;71(5):e139-e140.

doi: 10.1016/j.eururo.2016.09.034. Epub 2016 Sep 29.

¹ Unit of Urology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy. Electronic address: umbertocapitanio@gmail.com.
² Unit of Urology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy.

No abstract available

Comment on

Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.
Rini BI, Dorff TB, Elson P, Rodriguez CS, Shepard D, Wood L, Humbert J, Pyle L, Wong YN, Finke JH, Rayman PA, Larkin JM, Garcia JA, Plimack ER. Rini BI, et al. Lancet Oncol. 2016 Sep;17(9):1317-24. doi: 10.1016/S1470-2045(16)30196-6. Epub 2016 Aug 3. Lancet Oncol. 2016. PMID: 27498080 Free PMC article. Clinical Trial.